Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients

Peking University

Status: Completed

Conditions: Hepatitis; Lymphoma; Hepatitis B; Hematologic Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT02108444

PKU 2013-Autonomous-9

Details and patient eligibility

About

This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.

Full description

All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.

Enrollment: 107 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• treatment-naive patients with lymphoma
• patients with a history of previous exposure to hepatitis B virus (HBV): HBsAg or hepatitis B core antibody (anti-HBc) positive

Exclusion criteria

• HBsAg and HBcAb negative

Trial design

107 participants in 2 patient groups

group with HBV reactivation

Description:

group with hepatitis B virus reactivation

group without HBV reactivation

Description:

group without hepatitis B virus reactivation